Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Preventing Tumour Onset in Li-Fraumeni Syndrome by Inhibiting the Mechanistic Target of Rapamycin (mTOR)-Regulated Senescence-Associated Secretory Phenotype
FY 2017-18
Summary
Individuals with Li-Fraumeni Syndrome (LFS) are prone to developing early-onset malignancies because the TP53 tumour suppressor gene is mutated in all of their cells. p53 promotes DNA repair, cell cycle arrest, and death of pre-malignant cells, making malignancies associated with mutantp53 hard to treat. Thus, my research will focus on pharmacologically preventing cancer in LFS patients.Mechanistic target of rapamycin (mTORC1) pathway inhibition minimizes cancer rates in LFS mouse models, suggesting that mTORC1 is necessary for p53-dependent tumorigenesis. Evidence points towards the involvement of mTORC1 in promoting cell cycle arrest (senescence) and the release of pro-tumorigenic factors from senescent cells (senescence-associated secretory phenotype (SASP)), which are both enhanced in LFS patients and cell lines. Thus, I hypothesize that mutant p53 stimulates LFS tumour onset by promoting the SASP, and that the decrease in tumour onset following mTORC1 inhibition is due to a resultant decrease in the SASP.To assess whether the SASP promotes malignancy in LFS, I will culture non-senescent LFS fibroblasts in SASP factor-containing media and use microscopy to detect morphological and molecular changes associated with malignant transformation. To determine whether SASP inhibition prevents tumour onset, I will treat LFS mice with inhibitors of senescence and assess delay in tumour onset. To investigate whether mTORC1-mediated SASP promotes LFS tumorigenesis, I will treat LFS mice with an mTORC1 inhibitor, collect tumours from treated and non-treated mice, and assess differences in tumour and SASP factor abundance.The proposed work may validate mTORC1 inhibition as a method to inhibit SASP-driven tumorigenesis in LFS.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386340
Name
Giovino Camilla M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Preventing Tumour Onset in Li-Fraumeni Syndrome by Inhibiting the Mechanistic Target of Rapamycin (mTOR)-Regulated Senescence-Associated Secretory Phenotype
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Predisposition; Li-Fraumeni Syndrome; Malignant Transformation; Mtorc1 Signalling; Pharmacological Prevention Of Malignancy; Rapamycin; Senescence; Senescence-Associated Secretory Phenotype; Tp53
Abstract
Individuals with Li-Fraumeni Syndrome (LFS) are prone to developing early-onset malignancies because the TP53 tumour suppressor gene is mutated in all of their cells. p53 promotes DNA repair, cell cycle arrest, and death of pre-malignant cells, making malignancies associated with mutantp53 hard to treat. Thus, my research will focus on pharmacologically preventing cancer in LFS patients.Mechanistic target of rapamycin (mTORC1) pathway inhibition minimizes cancer rates in LFS mouse models, suggesting that mTORC1 is necessary for p53-dependent tumorigenesis. Evidence points towards the involvement of mTORC1 in promoting cell cycle arrest (senescence) and the release of pro-tumorigenic factors from senescent cells (senescence-associated secretory phenotype (SASP)), which are both enhanced in LFS patients and cell lines. Thus, I hypothesize that mutant p53 stimulates LFS tumour onset by promoting the SASP, and that the decrease in tumour onset following mTORC1 inhibition is due to a resultant decrease in the SASP.To assess whether the SASP promotes malignancy in LFS, I will culture non-senescent LFS fibroblasts in SASP factor-containing media and use microscopy to detect morphological and molecular changes associated with malignant transformation. To determine whether SASP inhibition prevents tumour onset, I will treat LFS mice with inhibitors of senescence and assess delay in tumour onset. To investigate whether mTORC1-mediated SASP promotes LFS tumorigenesis, I will treat LFS mice with an mTORC1 inhibitor, collect tumours from treated and non-treated mice, and assess differences in tumour and SASP factor abundance.The proposed work may validate mTORC1 inhibition as a method to inhibit SASP-driven tumorigenesis in LFS.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Giovino, Camilla M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~